Envirotech Vehicles, Inc. 8-K

What Happened Envirotech Vehicles, Inc. (EVTV) reported that director Melissa Barcellos informed the company on November 12, 2025 she would not stand for re-election and effectively resigned as of the reconvened 2025 Annual Meeting held February 3, 2026 (the meeting had been adjourned on December 30, 2025 and January 20, 2026 for lack of quorum). On February 9, 2026 the company notified Nasdaq that, because of Ms. Barcellos’s resignation, it no longer met Nasdaq Listing Rule 5605(b)(1) (majority independent board) and Nasdaq Listing Rule 5605(c)(2)(A) (audit committee of at least three independent members). On February 12, 2026 Nasdaq provided a cure period under Rules 5605(b)(1)(A) and 5605(c)(4) requiring EVTV to regain compliance by the earlier of its next annual meeting or February 3, 2027 (or by August 3, 2026 if the next annual meeting is held before August 3, 2026). The company said it intends to add an independent director who meets Nasdaq requirements before the cure period expires.

Key Details

• Melissa Barcellos informed EVTV on Nov 12, 2025 and did not stand for re-election; her resignation was effective at the reconvened 2025 Annual Meeting on Feb 3, 2026.
• The 2025 Annual Meeting was adjourned twice (Dec 30, 2025 and Jan 20, 2026) for lack of quorum and reconvened on Feb 3, 2026.
• Nasdaq granted a cure period (notice received Feb 12, 2026) to regain compliance with Rules 5605(b)(1) and 5605(c)(2)(A) by the earlier of the next annual meeting or Feb 3, 2027 (or Aug 3, 2026 if the next meeting is before Aug 3, 2026).
• Separately, Nasdaq notified EVTV on Feb 12, 2026 that the company had regained compliance with Nasdaq Listing Rule 5620(a) (holding an annual meeting within 12 months of fiscal year end); that matter is closed.

Why It Matters Loss of the required number of independent directors and audit committee members can trigger listing-delisting proceedings, so Nasdaq’s cure period gives EVTV time to appoint a qualified independent director and restore its audit committee without immediate delisting. Investors should watch for the company to name a new independent director and to confirm that the audit committee meets Nasdaq requirements before the cure deadline. The filing also includes forward-looking statements about the company’s plans to regain compliance; those statements are subject to the risks described in EVTV’s SEC filings.